Nonfatal asthma-related serious adverse events (SAEs) by age, sex and ethnicity (overall data set)
| Formoterol-containing products | Non-LABA-containing products | Total | |
| Age group | |||
| 4–11 yrs | 39/3264 (1.2) | 25/2165 (1.2) | 64/5429 (1.2) |
| 12–17 yrs | 24/4556 (0.5) | 17/1889 (0.9) | 41/6445 (0.6) |
| 18–64 yrs | 270/37882 (0.7) | 136/12596 (1.1) | 404/50478 (0.8) |
| ≥65 yrs | 43/4162 (1.0) | 21/1448 (1.5) | 64/5610 (1.1) |
| Unknown | 0/42 (0) | 0/0 (0) | 0/42 (0) |
| Sex | |||
| Male | 146/22057 (0.7) | 72/8068 (0.9) | 218/30125 (0.7) |
| Female | 228/27800 (0.8) | 127/10030 (1.3) | 355/37830 (0.9) |
| Unknown | 0/49 (0) | 0/0 (0) | 0/49 (0) |
| Ethnicity | |||
| Caucasian | 268/39868 (0.7) | 123/14818 (0.8) | 391/54686 (0.7) |
| Black | 8/861 (0.9) | 3/328 (0.9) | 11/1189 (0.9) |
| Oriental | 70/4065 (1.7) | 53/1916 (2.8) | 123/5981 (2.1) |
| Other | 25/2170 (1.2) | 20/1036 (1.9) | 45/3206 (1.4) |
| Unknown | 3/2942 (0.1) | 0/0 (0) | 3/2942 (0.1) |
| Total | 374/49906 (0.7) | 199/18098 (1.1) | 573/68004 (0.8) |
Data are presented as n/N (%) of patients reporting at least one asthma-related nonfatal SAE (defined using International Conference on Harmonisation recommendations). LABA: long-acting β2-agonist.